1,033 reports of this reaction
3.9% of all LEVODOPA reports
#3 most reported adverse reaction
PARKINSON^S DISEASE is the #3 most commonly reported adverse reaction for LEVODOPA, manufactured by Merz Pharmaceuticals, LLC. There are 1,033 FDA adverse event reports linking LEVODOPA to PARKINSON^S DISEASE. This represents approximately 3.9% of all 26,727 adverse event reports for this drug.
Patients taking LEVODOPA who experience parkinson^s disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PARKINSON^S DISEASE is moderately reported among LEVODOPA users, representing a notable but not dominant share of adverse events.
In addition to parkinson^s disease, the following adverse reactions have been reported for LEVODOPA:
The following drugs have also been linked to parkinson^s disease in FDA adverse event reports:
PARKINSON^S DISEASE has been reported as an adverse event in 1,033 FDA reports for LEVODOPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
PARKINSON^S DISEASE accounts for approximately 3.9% of all adverse event reports for LEVODOPA, making it one of the most commonly reported side effect.
If you experience parkinson^s disease while taking LEVODOPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.